A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer (Q44533503)

3 December 2017

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer (English)

1 reference

3 December 2017

1 reference

Sravanthi Cheeti

1

1 reference

3 December 2017

Nageshwar R Budha

2

1 reference

3 December 2017

Sharmila Rajan

3

1 reference

3 December 2017

Mark J Dresser

4

1 reference

3 December 2017

Jin Y Jin

5

1 reference

3 December 2017

26 February 2013

1 reference

Biopharmaceutics and Drug Disposition

3 December 2017

1 reference

3 December 2017

34

1 reference

3 December 2017

141-154

1 reference

3 December 2017

3

1 reference

The Simcyp population-based ADME simulator

3 December 2017

1 reference

The role of physiologically based pharmacokinetic modeling in regulatory review

21 January 2018

1 reference

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

21 January 2018

1 reference

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

21 January 2018

1 reference

Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women.

21 January 2018

1 reference

The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein

21 January 2018

1 reference

Disease-induced changes in the plasma binding of basic drugs

21 January 2018

1 reference

Human alpha-1-glycoprotein and its interactions with drugs

21 January 2018

1 reference

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance

21 January 2018

1 reference

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability

21 January 2018

1 reference

Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences

21 January 2018

1 reference

Bicalutamide: clinical pharmacokinetics and metabolism

21 January 2018

1 reference

NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.

21 January 2018

1 reference

The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects

21 January 2018

1 reference

An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers

21 January 2018

1 reference

Effect of glycyrrhizin on the activity of CYP3A enzyme in humans

21 January 2018

1 reference

Marginal increase of sunitinib exposure by grapefruit juice

21 January 2018

1 reference

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males

21 January 2018

1 reference

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

Population pharmacokinetic model of PI-88, a heparanase inhibitor

21 January 2018

1 reference

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients

21 January 2018

1 reference

Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.

21 January 2018

1 reference

The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics

21 January 2018

1 reference

Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling

21 January 2018

1 reference

The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients

21 January 2018

1 reference

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

21 January 2018

1 reference

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

21 January 2018

1 reference

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding

21 January 2018

1 reference

Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer

21 January 2018

1 reference

Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping

21 January 2018

1 reference

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

The binding of HIV-1 protease inhibitors to human serum proteins

21 January 2018

1 reference

Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

21 January 2018

1 reference

Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients

21 January 2018

1 reference

P-glycoprotein, multidrug resistance and tumor progression

21 January 2018

1 reference

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

21 January 2018

1 reference

Population pharmacokinetics of raltitrexed in patients with advanced solid tumours

21 January 2018

1 reference

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.

21 January 2018

1 reference

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/BDD.1830

1 reference

3 December 2017

1 reference